Open AccessImmune checkpoint inhibitors in the onset of myasthenia gravis with hyper CK emia
Author(s) -
Takamatsu Koutaro,
Nakane Shunya,
Suzuki Shigeaki,
Kosaka Takayuki,
Fukushima Satoshi,
Kimura Toshihiro,
Miyashita Azusa,
Mukaino Akihiro,
Yamakawa Shiori,
Watanabe Keisuke,
Jinnin Masatoshi,
Komohara Yoshihiro,
Ihn Hironobu,
Ando Yukio
Publication year - 2018
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.654
Subject(s) - medicine , myasthenia gravis , immunology , immune system
Abstract Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyper CK emia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyper CK emia related to immune checkpoint inhibitors. Moreover, we tested anti‐striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti‐striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyper CK emia with immune checkpoint inhibitors.